Essent Biologics, a nonprofit biotechnology startup emerging from two years of stealth-mode operation, announced its launch as a new venture to meet the growing need for human-derived biomaterials and data for regenerative medicine research. The company will also produce key inputs for further manufacturing by clinical partners.
As a new venture from AlloSource, one of the world’s leading manufacturers of fresh cartilage tissue used for joint repair and skin allografts, Essent Biologics will leverage its connection to human tissue donation by providing low passaged primary cell lines, origin tissue and comprehensive donor data to advance translational research from benchtop to bedside. The company can also serve as a biomanufacturing partner, creating a large inventory of custom products.
Essent Biologics will supply mesenchymal stem cells sourced from adipose tissue and Wharton's Jelly, produced under current Good Manufacturing Practices, as well as demineralized bone matrices for 3D bioprinting. The company has already partnered with leading academic research and biopharmaceutical companies who await Essent Biologics’ official product launch, anticipated in April 2021.
“We are proud to set a new standard in human-derived biomaterials for research,” said Corey Stone, Executive Director, Essent Biologics. “Essent will motivate and empower the work researchers are doing by supporting the development of innovative therapies through quality biomaterials and powerful data.”